Research Bytes podcast

Chandana Guha's journey into research was inspired by caring for her daughter, who has kidney disease. In this latest episode of Research Bytes she discusses how her personal experience as a caregiver deepened her insight into her field

• Listen to the podcast on Spotify.
• Read the publication

PROFESSOR ROBYN WARD

Welcome to Research Bytes. I'm Robyn Ward. I'm the Executive Dean of the Faculty of Medicine and Health at the University of Sydney. And I'm joined today by Chandana Guha. And Chandana is going to talk to us about some of her exciting work in renal disease. But firstly, I'd just like to hear a little bit about you, Chandana.

How did you come to be working in this really interesting area? 

CHANDANA GUHA
Thank you, Professor Ward. It's my absolute pleasure to be here today and share my research experiences. And thank you for the invite to be a part of, uh, Research Bytes. A little bit of a context.  I'm a caregiver of my daughter for the last 26 years.

And, she was diagnosed with childhood chronic kidney disease at the age of two. Her condition progressed rapidly. And by the time she was 10 years old, she was in kidney failure. She had kidney failure. And she was on dialysis. So I dialyzed her at home. we carried out something called peritoneal dialysis for a year and a half.

And then she received a transplant subsequently. But along with her condition, she also had, multiple comorbidities, which is very typical of children with chronic kidney disease. So we went through the whole cycle of the disease, starting with early disease we progressed to kidney failure advanced kidney disease, dialysis, and transplant.

PROFESSOR ROBYN WARD

And could you tell us a little bit about what it's like being a caregiver to someone who needs peritoneal dialysis? I don't think many people will potentially know what peritoneal dialysis is, so perhaps you could just tell us what that is and what it was like for you doing that.

CHANDANA GUHA
Well, it was heartbreaking to start off with to hear that your child's kidneys have failed and there is simply no way out other than to be machine dependent. So what happens is through a machine, they infuse fluid into your belly and then they take out all the toxins from your body and then we can dispose of that because that's the role of, the primary role of the kidneys is to clear your body of all toxins.

So we had to do that every day and she was tied to the machine 12 hours a day. So, we would do that through the night. However, we managed still to go to school. I managed to have a job, a part time job. My employer is very kind. And so she would go to school, come back. We would have one cycle for 45 minutes.

And then she'd do her homework. And then at night, again, she'd be back on dialysis for the whole night, about eight hours, eight to ten hours. And we did that for about,

one and a half years.

PROFESSOR ROBYN WARD

And so what was the difference between that life and the life after having a transplant?

CHANDANA GUHA
Transplant, of course, is a treatment.

It's not a cure. And that's something that, we need to be, I wasn't sure of. I didn't understand that at the time. At the time, there's very little, or at least I wasn't very literate, around what the impact of the, of dialysis was and what transplant meant to, to us. But yes, we were free of the machine, and we continued with our lives and my daughter could go back to school.

She finished university and But we definitely needed to be very careful about around her health, because she was on lifelong immunosuppressants, which suppressed her immunity, she was susceptible to a lot of infections and repeated hospitalizations and multiple complications, but that's the life of a transplant recipient

But through it, what I realized is that there are gaps between the health system and the patient. the patient. And that's the gap that I always wanted to, to bridge. 

PROFESSOR ROBYN WARD

So now we're, we're moving to hear about what got you into research. Obviously, you have this passion, um, and personal experience. So how did you turn that into research?

CHANDANA GUHA
Well through my journey caring for my daughter, I witnessed firsthand the mental, the psychological, and the social challenges that she faced on a daily basis and the profound impact it had on her quality of life. So the quality of life research is of very big importance to me because children with Or, or chronic kidney disease in children is very different from chronic kidney disease or CKD in adults.

CKD in children is associated with congenital anomalies, with heredity, hereditary defects, birth defects, and, um, a huge care burden and treatment burden, uh, and the disease burden itself. And all of this have, all of this have an impact on their on their life throughout their childhood and not only throughout their childhood, but it extends into their adult life impacting how they function, which means the longitudinal impact is very important for me and that that's what I was interested in to see how the quality of life varied over time across CKD stages.

PROFESSOR ROBYN WARD

And you managed to get this important work published in Kidney International, it's a very excellent journal, so tell me what your findings were when you did this study. 

CHANDANA GUHA
It's one of the most exciting and satisfying experiences that I ever had working in that project.

So we analyzed data from a study which is called the Kids with Chronic Kidney Disease Study, and where we recruited patients across Australia and New Zealand, school going patients aged between six to 18 years, and we had 377 participants that were enrolled from five hospitals and across all stages of kidney disease.

So we had about 199 pre dialysis patients, uh, 43 dialysis patients, and 127 transplant recipients at the time of enrollment. And then we followed them for over four years, but taking their details every two years. So, we had details at zero, that's baseline, at two years, and at four years. And then we analyzed that data using a multivariable linear mixed model, and we adjusted for sex.

We adjusted for socioeconomic status gender and comorbidities and age as well. And what we found is in these three groups, that is, you had predialysis, dialysis, and transplant the way their quality of life scores changed, was very different.

So for the pre dialysis and the transplant recipients, their quality of life scores remained stable over time.

But for those who were on dialysis, their scores changed. just went up. So it improved over time, over the four years. And we went back and saw why that happened.

And we saw that most, over 50 percent of those who were dialyzed, who were on dialysis at the start of the study had received a transplant, which is why their quality of life scores improved.

We measured quality of life using a tool called the Health Euclid Index or the HUE 3, which captures the total impact of the disease, uh, across different domains. So you have it looked at the impact on vision, on pain, on cognition, on hearing speech, dexterity, ambulance. 

PROFESSOR ROBYN WARD

And how do you do that in a young child. Is the child doing it or is their caregiver doing it? Who's filling in these forms? I've seen them. They're, they're sometimes quite complicated.

CHANDANA GUHA
It was  parent reported and self reported. It was a mix of the two.

PROFESSOR ROBYN WARD

And do you think the, the children became better at filling them in obviously as they got older?

How do you tease that apart when you're doing a longitudinal study and perhaps the child is less able to do that when they're younger and then they get older and they're more capabilities to fill in these forms.

CHANDANA GUHA
Yeah, that's, that's one of the, the issues or limitations that you have multiple people filling it out at the early stages, their parents.

And then as they go on, because often there is that little bit of a discrepancy between a parent reported and a, and a self reported, uh, questionnaire. So the scores are a little different, but well, that's the, we've got to live with that. 

PROFESSOR ROBYN WARD

That's exactly right. And how do you think this information will be used.

I guess maybe I, I think back to, to that journey you told us about with your daughter. Why would this information be of use to you when you first heard the diagnosis of your, of your daughter's kidney disease? 

CHANDANA GUHA
First and foremost, the fact that life does get better. After you have a transplantation is a very, very important information, not only for us as patients, but also for policy makers.

And that's because you need to improve or you need to make sure that these kids who are on dialysis and who are suffering because they have the poorest quality of life scores in comparison to the rest of the transplant cohort. They have their mortality rates are between 30 to 50% higher than the general public.

So we really need these children on dialysis to go on to transplants, and that means we need to have that a lot more exposure around how we improve donation rates and how we, we, preserve organs, you know, new, better technology to preserve organs, more access to care, more access to transplantations, easier screening processes, and alsothat bit of financial assistance to families to be able to access that, that care.

Especially for example, if you're looking at those who are from socially and economically disadvantaged backgrounds, they have issues accessing care, and that's, that's one of the, that's what our studies found out subsequent to that, that it's one of the biggest problems is accessing care, whether it's for dialysis or whether it's for transplant.

So, making sure that they. move on from that stage to that, to transplant is what we want. 

PROFESSOR ROBYN WARD

I think that  the findings of your study are just so impactful, as you've said, in so many ways. But, really I think for people who are a parent thinking about may be fearful about transplantation even when it's offered are fearful of the consequences of immunosuppression.

You know, this is, this brings a lot of confidence for those decision makers to, to really think, well, actually my child's life's going to be a lot better if I take this risk because, you know, it's going to be a better life, even though there are obviously, as you say, consequences of living with a transplanted kidney.

It's better than living on dialysis.

CHANDANA GUHA
Absolutely.  And especially there needs to be that information and education out there on how you manage yourself once you're on transplant, adherence to medication, keeping yourself safe from infections and all of that.

So the message that I want to get through is it is possible to live a healthy life or a full life despite having a transplant, but you've got to take those precautions and you've got to make sure that you do your bit and then you can leave the rest to the healthcare providers.

PROFESSOR ROBYN WARD

Chandana, I would be really interested to hear how your daughter is. Tell us a little about her accomplishments. She's a grown woman now. What's her life been like?

CHANDANA GUHA
well, she had a very, very difficult life for the first 18 years, literally we were in and out of hospitals.

I was so comfortable with being at the kids hospital. It was like a second home to me. We would be there all the time. So she missed out on a lot of schoo because of treatment and all of that.

But she did manage to complete year 12and then she finished she has a degree of art from the University of New South Wales.

And yeah, she's a graphic designer. She lives independently, which was something that I couldn't even imagine ever that we would have a life like this where I am in research doing, I just love this work that I do and the people that I work with.

And she's able to live on her own, do things by herself, have a  little job and, um, and independent. That's important.

PROFESSOR ROBYN WARD

I think your story and the work you've done and publishing that work is really a very strong illustration of how important it is.

Research involves and is often led by people who have had lived experience of the conditions because the research is often much more focused on what the real problems are than what the and really draws out the policy implications of these sort of findings and hopefully helps decision makers and maybe motivates the public in this case to understand how important it is to have kidney donations.

It's transformative in people's lives and you've shown that particularly with your work in children about how difficult and impactful it is to be on dialysis as a child.

So we'd really like to understand how you've managed as an early and mid-career researcher. And if you don't mind me saying a mature early and mid-career researcher, what are some of the challenges you've experienced?

CHANDANA GUHA
I will talk about challenges and benefits as well, Robin. It's been my absolute pleasure to be in research because I've had very, very, a very supportive research team. My supervisors, Professor Allison Jerry and Professor Wong, have been superb in in supporting me because they really understand, My issues around caregiving because as a caregiver, I wasn't able to dedicate 100 percent of my time all the time to research.

I had to be at the hospital a lot of time. So having flexible work arrangements really worked for me. And I had all those and I had their support through that. But what when I look at myself, I think I've got all those variables. I represent all those variables that people adjust for in their models age, gender, ethnicity, and as an early migrant I struggled financially, low SES.

So all of that they adjust. And I must say that  because of the research environment, I was able to, to accomplish what I did, that was wonderful, and also through my research, I got back, um, because as a caregiver, you're really invisible, no one sees you, and we become like that, but I was able to be, come out and talk about my research, which I'm so passionate about, get back years of research.

That I'd lost in caregiving. 

PROFESSOR ROBYN WARD

I want to really thank you, Chandana, for all your work. It's been wonderful to speak to you here on Research Bytes. 

OUTRO: That was Research Bytes, and we came to you today from Gadigal land. Thanks for listening. You can listen back, read the paper, and find the transcript on soundcloud.com/fmh-news

Dr Qingwei Luo shares her fascinating statistical modelling of large scale health data, projecting cancer rates in Australia over the next 2 decades. Her findings published in Lancet journal could improve our health system's preventative measures and treatments.

• Listen to the podcast on Spotify.
• Read the publication

PROFESSOR ROBYN WARD
Welcome to Research Bytes. My name is Robyn Ward and I'm the Executive Dean of the Faculty of Medicine and Health here at the University of Sydney and we're coming to you today from Gadigal land. I'm joined today by Dr. Qingwei Luo, who is a very expert researcher in cancer and in predicting cancer mortality and mortality from other diseases.

We're going to have a really interesting conversation with her today about some of her amazing work. Could you tell us a little bit about yourself? How did you come to work in this area? And what is your background? 

DR QINGWEI LUO
So I did my PhD in the University of Sydney when I was working full time at the Cancer Research Division of the Cancer Council New South Wales.

So actually I started working on cancer incidence and mortality projections when I was in the final stages of my PhD study. 

PROFESSOR ROBYN WARD
And I think you've done some really interesting work in a couple of areas, but I think everyone's pretty keen to understand why they're going to die and whether they're going to die earlier than predicted.

And one of your very important research papers is about premature mortality, which is defined in your paper as anyone dying before the age of 75. If you look at your predictions of what people will die of over the next 20 years, what have you found? 

DR QINGWEI LUO
So actually, our Projections model show that over the next 25 years, cancer remains the leading cause of premature death in Australia and followed by cardiovascular disease.

So that means a lot of premature deaths in Australia can be prevented. And the ways in the cancer for males, lung cancer, colorectal cancer, and the pancreatic cancer, prostate cancer are the leading cause of premature death for males. 

And for females, slightly changed, but still lung cancer, breast cancer and colorectal cancer, pancreatic cancer are the leading cause of premature death.

PROFESSOR ROBYN WARD
That's really important for, I think, people to know because sometimes there's not a good understanding of which of these cancers could be prevented and where work needs to go in order to reduce the burden of cancer and also the death from cancer in those groups that you were talking about. The other thing you've done is actually look in a more detailed level as not just cause of death, but incidence of cancer over these next 25 years.

What in your study do you show as increasing cancers in our community in Australia over the next 25 years? 

DR QINGWEI LUO
So our projections show that cancers of the female breast, kidney cancer, Liver cancer and pancreatic cancer actually show increase in trend rather than decreasing or relatively stable as the other cancer types.

PROFESSOR ROBYN WARD
And I think people would be keen to know if people are diagnosed with the cancer, what's happening now in the mortality, is it different mortality rates over the next 25 years predicted from people who actually are diagnosed with cancer? 

DR QINGWEI LUO
Yeah, actually for mortality rates, actually the good news is most of the cancer type showing decreasing trend in the next 25 years or at least relatively stable.

So the only notable increasing pattern we projected are the cancers of liver and the uterine cancer. In particular, uterine cancer actually very low, right? So this means actually over the time we improve this cancer survival, and also improve the cancer screening or detection. Early detection, of course also contribute to the control of risk factors such as tobacco smoking, alcohol consumption, or other factors that contribute to the increasing in the cancer risk.

PROFESSOR ROBYN WARD
So these interventions that are happening in Australia and internationally on prevention, onscreening, and then on better treatments are all working together to reduce the chance of someone dying of a cancer now, than what that or in the next 25 years than what has happened in the past where the mortality was very high with a lot of cancers.

DR QINGWEI LUO
Yeah, that's very true. 

PROFESSOR ROBYN WARD
And what do you have a sense just of whether there's a different contribution is some things really, some of the cancer mortality is reducing more because of better treatments, or is it because of things like stopping smoking, better prevention programs, better screening programs? 

DR QINGWEI LUO
For different cancer types, because the factors driving to the pattern are different. For example, lung cancer, I think currently the major factor driving the decrease in in trend in both the incidence and the mortality or for the tobacco smoking is tobacco control over the past few decades, actually, is a major factor, to reduce the lung cancer incidence and the mortality. 

And of course, we anticipate in the future, we also recently planned for the lung cancer screening and the other targeted, uh, treatment will also contribute to the future cancer mortality decrease. 

For colorectal cancer, so we know Australia have organised the screening, bio cancer screening program implemented from 2006. We have other teams working on optimising the screening program to see if we should include younger people. So our baseline projections also as a fundamental benchmarking projection to fit in that program. 

PROFESSOR ROBYN WARD
Now, I think what you're moving on to, which is a really important area is that screening has largely been age based, not necessarily risk based.

I think some of the new technologies, particularly possibly using, you know, polygenic or multiple genes to actually test someone to see what cancers they are at risk of and then targeting the screening to that group rather than targeting everyone has real exciting possibilities and your work on the modeling of how that would apply is going to be really vital because we can't run large screening programs doing polygenic risk scores and measuring things.

We rely on modelers like yourself to actually make these really important predictions. 

You touched then on colorectal cancer, which is a topic I'm very keen to talk to you about. 

And I think most people would know that if you identify a polyp or a pre cancer in a bowel early, then it's completely curable and unlike other cancers, which start off, you know, sometimes very small, but have already spread throughout the body, bowel cancer is a very largely a very organised cancer.

It works its way growing bigger and bigger and then eventually spreads. 

So the bowel cancer screening program is ideal for this sort of a cancer because caught early, it's curable, and it's great to see that we're actually predicting there'll be a huge decrease in death from bowel cancer because of that early diagnosis.

But what you did show in one of your studies was those delays in the health system which occurred during COVID had a particular impact on colorectal cancer. 

DR QINGWEI LUO
So when we did the baseline projections for all cancers incidents and mortality, when we finished that work, it's just during the COVID 19 pandemic.

So we try to build on that work as a benchmarking projection and we evaluated what will, what will, be subsequent, uh, impact if the cancer patients was delayed in receiving treatment after diagnosis or during their survivorship. But because we don't have real time treatment data, so potentially that kind of modeling is really a mix of this, hypothetical scenario.

We know Australia did very well in terms to control the COVID 19 pandemic in that time period. So potentially our projections for the treatment delay might not  really happen in Australia. That's the good news. The key thing we found, if the impact of mortality due to treatment delay actually largely depend on the length of the delay.

So, potentially, the longer delay, it's not a linear relationship. The longer delay may have a more dramatic risk of death from cancer. Of course, we want all the patients can receive timely treatment to be able to cure the cancer. So that's kind of the work we did. 

PROFESSOR ROBYN WARD
Yeah, I think that was such an important part of that study is that it, you really did show through modeling, I recognise it's not, you know, haven't measured the data, but through modeling that if there is a delay in diagnosis and then implementing treatment, in this case, surgical treatment, and then the follow up care, then the risk that someone will die increases.

And, and you've, actually calculated how many lives would be lost if those delays played out in real time.

So, I guess bringing that all back to your original study, it's really important from the Australian healthcare system planning point of view to know which of these cancers are likely to cause death. 

Which are less likely to cause death. And if the system is in any state of challenge because it, you know, has another pandemic, hopefully never, then we really need to focus our efforts on those things that we absolutely need to treat as early as possible.

I think that's a really important part of the modeling work you've done. And as a consequence had two really amazing publications in Lancet, I could see how much work has gone into them. So I really want to thank you for your work and the work of your team. 

DR QINGWEI LUO
Thank you so much. 

PROFESSOR ROBYN WARD
So thank you for joining us today on Research Bytes.

And we came to you today from Gadigal land. Thanks for listening. 

OUTRO
You can listen back, read the paper and find the transcript on www.soundcloud.com/fmhnews

Dr Tess Reynolds is redesigning CT scanners for real-time use in surgery. Her research looks at delivering the future of interventional imaging in challenging surgical scenarios.

• Listen to the podcast on Spotify.
• Read the publication

PROFESSOR ROBYN WARD: 
Welcome to Research Bytes. My name is Robyn Ward and I'm the Executive Dean of the Faculty of Medicine and Health at the University of Sydney. And I'm joined here today by Dr Tess Reynolds, who's going to talk to us a little bit about herself. And then we're going to get into a conversation about her research findings. So, Tess, who are you and what do you do?

DR TESS REYNOLDS:
So I had a bit of an unconventional path to get where I am today. So I have undergraduate degrees in astrophysics and my honours is also in astrophysics, all done at the University of Adelaide. And then I had an inspirational lecture by my then PhD supervisor, Professor Tanya Monro, who's now the Chief Defence Scientist on photonics and the amazing work that optical fibre could do, and how that can help the biomedical space. And so I went and did that as my PhD. Loved it, fell in love with research. But then at the end of it, I really needed sort of a change of pace and a different research direction. And then I found this opportunity here at the University of Sydney, working in medical physics and developing new imaging protocols to help in the medical space. And six years later, I'm still here.

PROFESSOR ROBYN WARD: 
Fantastic. And now you've published a really nice paper in investigative radiology, and I'm going to ask you to explain what you've done to a layperson who doesn't have a degree in astrophysics.

DR TESS REYNOLDS:
Sure. Well, definitely it's not as complicated as astrophysics, but basically the whole premise of my research is trying to expand the capabilities of these amazing robotic imaging systems that are now found in a lot of surgical suites in hospitals around the world, and that they are often really, set up to target, you know, key areas such as cardiology, radiology, neurology. But they have so much more to give, and to allow them to be expanded to new disciplines such as orthopaedics, which is what we're targeting with this paper, we need to work on, developing imaging techniques that are specific to those disciplines.

So in the orthopaedic space, one of the challenges is that they're often dealing with large pieces of anatomy, such as the entire spine. And to be able to capture that in a single image in the operating room is currently well, until our paper came out, wasn't really, an achievable goal.

So we were really focussed on trying to bring in the imaging capabilities of standard things such as CT and MRI which you have outside of operating room into the interventional space, and to allow them to have, you know, this instant coverage of the entire piece of anatomy visualised in 3D in the surgical room, like they do pre and post the surgery to allow to improve navigation, guidance, decision making, and also importantly, really determine at the end of the procedure are they satisfied with the work that they've done.

Because unfortunately, often what we find is that then the patient will be imaged in post and they'll find that, oh no, that something hadn't gone completely right in the surgery. And the patient has to have a second corrective procedure. This is extremely expensive. It's dangerous to the patient, to have to have another procedure. So if they can make those decisions in the room, that will help a lot. And so that's what we really focussed about trying to bring that imaging into that space.

PROFESSOR ROBYN WARD: 
So tell me what was wrong with the current imaging modalities we have in an operating theatre. And what did you do that actually makes that imaging much better?

DR TESS REYNOLDS:
I guess it's just at the moment they're really focussed on specific applications, and so they're not really taking advantage of the entire mobility and flexibility of these really cool, state of the art robotic systems.

So they operate in very simple, trajectories. So they would just go once around the patient in a circle and, and not really look to expand the coverage of the entire anatomy, say. So here we combined both, changing how the gantry rotates around the patient as well as the table. So we're moving the table and the gantry simultaneously to almost mimic what you get in a standard CT, which has the table translate as you're imaging the patient. And therefore you can have this huge coverage of virtually any piece of anatomy that you like. And so we haven't seen this in the interventional space before. A lot of it is also then just due to getting things through regulatory approval. And you know, that can be a complicated thing. So it's not to say that it wouldn't have come in the future, but we've just proven here that we're able to do it.

PROFESSOR ROBYN WARD: 
And tell me what a gantry is.

DR TESS REYNOLDS:
Oh, sorry. Yes. So the gantry is the device that houses both the X-ray source and the detector panel. It's often in a C shape in this case. So you have the detector on one end, the source and the other, and it's sort of connected by a big -shaped arm. That then is attached to a giant robot that is able to move around the patient.

PROFESSOR ROBYN WARD: 
So next time someone's lying in a CT scanner, they'll now very authoritatively be able to say, that's the gantry.

DR TESS REYNOLDS:
Yes. And in a standard CT scanner, it's more of an ‘O’, so it's fully enclosed and continuously rotates around the patient. Whereas for us we have it in a C form.

PROFESSOR ROBYN WARD: 
And just to elaborate a little bit further on, what was specifically your intervention or your discovery that made this paper get into a very important journal.

DR TESS REYNOLDS:  
So this was the first time that we'd actually proven in clinical hardware that this was possible in terms of being able to extend the field of view from the standard 17cm all the way to 80cm to allow large pieces of the anatomy, such as the entire spine to be captured in a single 3D volumetric image in the interventional room.

PROFESSOR ROBYN WARD: 
That's fantastic. That was one of the things that struck me was this longitudinal change was pretty significant, particularly if you're dealing with things like spinal surgery. So how do you prove that? Now, you obviously don't go and do this on a human being on day one, do you?

DR TESS REYNOLDS:  No. Absolutely not.

PROFESSOR ROBYN WARD:
So how do you prove these sort of things before you start moving these sorts of kit into an operating theatre?

DR TESS REYNOLDS:
Yes. So we have a number of processes. We first start, you know, potentially in just a simulation. So doing it all on computers and then we can move into what's called physical phantoms which are replica, you know, often made of plastics and other materials that when imaged will image equivalent to a human. And then for this paper, we were able to push all the way to animal cadavers. So the animals had already been deceased. But then we were able to image the anatomy that replicates close to humans and get an idea about image quality and final dose and stuff like that, before we actually determined it's safe and useful for humans.

PROFESSOR ROBYN WARD: 
And how replicable is this technology when you're moving from a dead animal to a living human? And there's lots of movement going on. Humans, for instance, breathing to start with. So how do you compensate for that?

DR TESS REYNOLDS:
So that's actually the next step in this work that we're actually undertaking right now is incorporating movement in there. So as you said yes, there's no breathing motion. There's no motion of the heart or other arteries. So we're looking at actually, we've developed a carotid artery phantom that has the entire arterial chain. And then we connect this to a pump that pulses. And so we're in the process of testing this protocol on that phantom to understand the motion. And then if that goes well we can apply for ethics and do this in live animals to again to get that understanding of how are we going to compensate for that motion, before moving on to humans.

PROFESSOR ROBYN WARD: 
And how do you compensate for that movement?

DR TESS REYNOLDS:
So we can do it two ways. So from the hardware point of view, we have a whole other series of work that really syncs the hardware with the patient. So we monitor for either a breathing rate or an ECG signal. And then we're gonna adapt how the acquisition occurs in terms of we might speed up or slow down the gantry rotation and sync when we're actually going to acquire each individual x ray.

We can also look on the software side that once we've got all of our images, we can do some really fancy mathematics before we produce the final image, that actually helps us compensate for all that motion.

PROFESSOR ROBYN WARD: 
How receptive are surgeons to having this sort of kit in the operating room with them? Is this a received as a positive thing or not so positive?

DR TESS REYNOLDS:
The surgeons that I've worked with, they've all seen this is an extremely positive thing. So we do have to be careful to not say that the surgeons, you know, are not good enough at their jobs, but it's more it's like a tool to help them to be better and to just remove that sole reliance on their experience. And also it really helps in the early stages of their career to ensure and get that live feedback of what they're doing.

It also significantly reduces the procedure time. And so that's where we see the most positive uptake, that if they know that their procedure can be done in a shorter period of time in a safer manner, they're very excited to get on board and support our research.

I've definitely got a big new appreciation for what surgeons do in terms of reading through anatomy textbooks and then seeing some of the procedures performed. You know, I have no idea how they go from one to the other. So in terms of giving them those images to, you know, really visualise every little bit of the bones and all the vessels and, and everything around. It's just so useful for them.

PROFESSOR ROBYN WARD: 
Could you just tell us a little bit about what's next for you, Tess, in this exciting world that you're pursuing? You’re not going back to astrophysics, I presume?

DR TESS REYNOLDS:
No. Definitely not. So in this space, we're continuing to look for new disciplines to help deliver the specific imaging for their needs. So we're looking to push into pulmonology and other thoracic interventions that have respiratory motion in the imaging and trying to compensate for that.

So we’re also getting into the 3D print space, which is really driven about also continuing to improve the safety of these procedures. So we take the images that were required and then the surgeons go in segment out the 3D print replicas of the procedure that they're going to perform, and then they practice that procedure. So we're really focussed with some surgeons out of Westmead Hospital in replicating the bone in the 3D print, so that the practice procedures feel like real bone, and so that they can confidently rehearse and train for that procedure before they go and do it.

So this is some early work that we hopefully will publish on this year, and maybe I can come back and talk about that project next year.

PROFESSOR ROBYN WARD: 
That would be great to hear about that. And I think just anyone out there who's going to have an operation or may have an operation in the next few years should feel really much more confident about all of the outcomes that they will have because of this sort of work.

I think it's very underestimated how important this sort of work is to the surgeons, to the procedures that are done themselves, and to just making sure when the person is actually doing an operation on you, it's a very best outcome that you could possibly anticipate.

So with that all, thank you Tess, it was great talking to you. I really enjoyed the conversation. I think I understand a little bit more about it than I did at the beginning, and we look forward to welcoming you back another time.

Thank you for joining us on Research Bytes. And we came to you from Gadigal land.

OUTRO:  
Thanks for listening. You can listen back, read the paper and find the transcript on soundcloud.com/fmh-news

Dr Katrina Champion's research looks at how early intervention on the 'big six' lifestyle risk factors could prevent chronic disease later in life. But her latest publication was not what they expected to find.

• Listen to the podcast on Spotify.
• Read the publication

Still to come

Dr Rachel Visontay looks at the long-term health effects of alcohol use. Her recent publication asks whether a little bit of alcohol might be good for depression.

• Listen to the podcast on Spotify
• Read the publication

PROFESSOR ROBYN WARD

Hello, my name is Robyn Ward. I'm the Executive Dean of the Faculty of Medicine and Health at the University of Sydney. And this is a podcast called Research Bytes. And today I'm here with Rachel Visontay, who's working on a very important area of alcohol and depression. And I'm sure this is going to lead to a lot of interesting conversations. But first off, let me introduce Rachel and ask her to tell us a bit about herself.

DR RACHEL VISONTAY

Thanks so much for having me on. I finished my PhD last year. So I'm a fresh postdoc in the faculty here, I worked as a research assistant at the Matilda Centre, where we focus on mental health and substance use, I was working there for a few years really embedded in the research, and was looking for sort of a meaty topic that I could pursue for my PhD.

And I came across this area of alcohol and long term health. And the particular controversial issue, which was whether for some health outcomes, there might actually be a protective effect of a little bit of alcohol consumption, as opposed to just those harms that we know about heavy levels of drinking.

PROFESSOR ROBYN WARD

And just tell me what you describe as high risk alcohol consumption, because I think that's quite important for us to establish at the beginning, there are a continuum of alcohol consumption from abstinence right through to high risk.

DR RACHEL VISONTAY

Well, there's no consensus on that on unfortunately. So for the most part, I go off the Australian guidelines that are issued by the NHMRC. But in the research that we're going to be talking about today, I was actually using some American data.

And in that case, we were using the American guidelines, which are quite a bit higher and have different thresholds for men and women. So this is actually a bit of a problem with the research is that there is no consensus from country to country as to what constitutes moderate drinking. And what constitutes risky drinking

PROFESSOR ROBYN WARD

So you didn't distinguish between men and women in terms of alcohol consumption, so you don't subscribe to that idea, there's a difference between men and women?

DR RACHEL VISONTAY

There definitely is in terms of how men and women metabolise alcohol, and it's to do with the fat distribution in the body. So there are definitely physical differences there. But I suppose the health bodies that are making these guidelines on a national basis, they make different decisions based on what evidence they have before them. So the Americans have gone with different thresholds for men and women.

Although, again, what constitutes a standard drink differs between countries as well. So the Americans are a bit more tolerant there, they've got it a higher threshold, whereas in Australia, they decided to just make a uniform number of standard drinks per week between men and women. And I suppose that's in an effort to simplify the guidelines. And also around the more conservative side.

PROFESSOR ROBYN WARD

Now, we've established that it's very hard to define alcohol consumption, let's move on to the issue of what you described, and how you discovered this relationship between alcohol and depression, which was previously perhaps thought of in a different way.

DR RACHEL VISONTAY

I think a lot of us know that there's a strong link between very heavy and disordered alcohol consumption and higher rates of depression. But depression is one of these outcomes that keeps popping up, where there seems to be this J shaped relationship.

So you start off with people who totally abstain from alcohol, and their risk for depression. And then you go down to people who drink a little bit moderately, and their risk drops off a little bit. And then as people drink more and more, that risk steadily climb. So that that looks like a bit of a J shaped.

But the debate in the literature was, you know, does this relationship actually reflect cause and effect? Or is it simply an association, that sort of an artefact from the way that we've been limited in conducting studies thus far.

PROFESSOR ROBYN WARD

And it seems in your paper, which was published in the American Journal of Psychiatry, you used a new statistical methodology. And I think most of our audience are not sort of super statisticians. But perhaps you can explain in simple terms, what was really novel about using this new methodology.

DR RACHEL VISONTAY

So I think that the biggest problem with a lot of this kind of epidemiological research in the alcohol world is that we run into something called confounding.

So we know that people who drink occasionally or moderately tend to have a lot of other health protective factors, like being wealthier and being better educated. So it's really hard to know if it's the alcohol that's causing health protection, in this case, better mental health, or whether it's those other factors that are causing the health protection.

So obviously, we have statistical methods to try to control for those confounders. But the standard methods that we use can really only be applied in a simple case, for example, where we measure alcohol once we measure those confounding variables once and we measure the health outcome once at the end, and that doesn't really capture the complexity of the kind of longitudinal relationship that is of interest and also of public health relevance.

We know that people's drinking can change over time. So it's really important to capture those changes, something we call drinker drift, and also their values on those confounding variables. We talked about, like how much money they're earning, whether they're in employment, those things are changing over time as well.

So the statistical method that we were using something called a marginal structural model that allows us to look at the relationship in any kind of complex longitudinal way, while still controlling for those confounding variables.

PROFESSOR ROBYN WARD

And now tell me about the data you use, because you've already touched on this idea that you need to collect longitudinal data, meaning is a data point, say for someone at the age of 12. And then later on, and later on, and then you get to the 50 year age group, where did you get all that data from?

DR RACHEL VISONTAY

We used a data set called the National Longitudinal Survey of youth from the states, the people in this data set we interviewed from when they were quite young, 14 to 22, was when they were recruited.

That's really, really handy for us because we can have information about people's drinking, right back from when they kind of started drinking, we ended up using about three and a half 1000 People from this cohort, which is a pretty substantial number.

PROFESSOR ROBYN WARD

So is there any difference in Americans drinking and drinking in Europe or drinking in Australia, would you imagine that will be different or these signings broadly applicable?

DR RACHEL VISONTAY

Well, this one really comes down now to the mechanisms. So we found that indeed, occasional or moderate drinking did seem to have this protective effect against depression. But we weren't really able to tease apart whether that is purely because of alcohols effects on neurotransmitters like dopamine and GABA, or inflammation, or whether the effect is pub's mediated more through social interaction and social support, you know, that alcohol facilitates social interaction.

So if it's predominantly the former, you would hope that that would be consistent from country to country, obviously, the social context might differ a little bit in different countries, in terms of the differences between drinking in Australia and the USA, it's fairly similar.

We have higher rates of binge drinking. Unfortunately, that's not a good claim to fame for us. And the US also has higher rates of overall abstinence.

PROFESSOR ROBYN WARD

And I was also interested in how you define depression. So that's fascinating, you use the scoring system for depression. So can you tell us about how you define depression in this study, and then what that means, in real terms to the average person walking along the street.

DR RACHEL VISONTAY

So everybody in this study, and this is similar for other kinds of cohort studies like this, were administered a sort of validated scale assessing a range of different depressive symptoms. So they might ask you about how often you felt hopeless in the past couple of weeks.

And so we looked at two different outcome measurements. One is just the number of symptoms. So your average score on that scale. And the other one was using a cut off on that scale. A probable yes or no for depression.

PROFESSOR ROBYN WARD

So here's the million dollar question Should all those people who are abstinent from alcohol begin drinking moderately so that they're going to feel less depressed?

DR RACHEL VISONTAY

Absolutely not.

As I said, there are a couple of outcomes for which this sort of J shaped effect keeps popping up. So depression is one of them. diabetes, type two diabetes is another maybe dementia.

But for a lot of health conditions, we know that every single drink is going to increase your risk. And that includes cancers at many, many sites, in some in aggregate alcohol is not good for us.

The other problem is that we don't know who's going to be able to maintain drinking on an occasional or moderate level, keeping their drinking levels underneath those recommended guidelines, and who will actually go on to develop alcohol use disorder. So definitely not a recommendation.

PROFESSOR ROBYN WARD

So do you think one of the main sort of implications of your study then are really around looking for the mechanisms between depression and alcohol?

DR RACHEL VISONTAY

Absolutely, yeah. So if there is a benefit there, finding out what those mechanisms are means that we can identify potential targets for intervening on using some kind of intervention that's not alcohol, that doesn't also entail risk for things like cancer.

So for example, if social support is the main mechanism, then we know there are a host of other ways to improve people's level of social interaction and social support, and we can focus on those instead. I think it would be really fascinating to do some further research, where we try and tease apart whether it's the social interaction, or the more direct biological mediation that's causing these benefits for depression. We'll see how my NHMRC application goes on that one.

PROFESSOR ROBYN WARD

It's been great talking to you, Rachel, thank you for joining us on Research Bytes and we came to you on Gadigal land.

VOICEOVER

Thanks for listening. You can listen back, read the paper and find the transcript on https://soundcloud.com/fmh-news

Dr Caitlin Jones aimed to investigate the efficacy and safety of opioids for low back pain, and uncovered some interesting findings in her research.

• Listen to the podcast on Spotify
• Read the publication

ROBYN WARD

Hello, everyone. My name is Robyn Ward. I'm the Executive Dean of the Faculty of Medicine and Health here at the University of Sydney. And welcome to Research Bytes. This is our second podcast. And the podcast is designed to profile some of the amazing work of our early and mid career researchers, and particularly those who are having impact on an international stage. And today, I'm joined by Caitlin Jones. And I'm going to first ask Caitlyn to tell us a little bit about herself. And then we're going to talk about her really important study about opioids and back pain. So Caitlin, where do you come from? And how long have you been at Sydney Uni?

CAITLIN JONES

So I come from a background of clinical work as an occupational therapist. I did that for a couple of years. And then I guess, just got curious about what else was out there. And I thought about doing some research. And I got some good advice early on that when you're thinking about doing research to go looking for the best supervisor, you could imagine, and to choose that person as the primary thing and let the exact topic be a secondary thing. So I went scouring through the internet to find someone that I thought would be an excellent supervisor and mentor. And I found Professor Christine Lin, and she was based at Sydney University. So I approached her and asked for a shot. And now here I still am years later

ROBYN WARD

Fantastic. And the paper you've got published is in the Lancet. And I think for people who don't know how important that journal is, perhaps they aren't working in this field, because it's extraordinarily important journal, particularly because it's influential with clinicians. And it's also very hard to get published in The Lancet. So congratulations, that's a major achievement. And the topic you've researched is back pain. And I don't think there'd be a single person out there who doesn't know someone or doesn't experience back pain themselves, acute back pain or chronic back pain. And I know personally from my own experience of having back pain, it's very painful and debilitating and can cause a lot of morbidity and mortality. And a lot of people use opioids for pain, despite the guidelines, because they think that that's going to help the pain and the pain is so severe that they feel there's nothing else to do but to take opioids. So your study was really very interesting, because you've made some different observations to what we have traditionally thought. So perhaps if you tell us about what you found, and why you think it is so important.

CAITLIN JONES

Yeah, sure. So like you said, Back pain is the most burdensome health condition in Australia and around the world from both the perspective of how much disability it causes people and what it costs the country to manage it as well. And you're right that a lot of people use opioid pain medicines for back pain. It's actually currently still in the guidelines to be considered as you know, a second or third line treatment when other things have failed. But that that recommendation wasn't based on any direct evidence before, it was sort of based on the assumption that an opioid pain medicine, being a strong painkiller would be suitable for severe pain like acute back and neck pain. But until the OPALtrial was done, we didn't actually have a good idea of how well it worked to compare that to the harms that opioids can cause which are serious and many. So yeah, the opioid trial was conceived by Professor Christine Lin and I got to join the trial as a PhD student. And we had a really surprising outcome. So we took about 350 people, and we randomly assigned them to either get a short course of an opioid pain medicine or a placebo, meaning nothing is a pill with it's made out of starch. And we followed them up for a full 12 months to see how they fared in terms of pain and function and quality of life and any short or long term side effects they had. And surprisingly, we found that in the short term, the people that took an opioid were no better off compared to the people that took a placebo. So there was no benefits in terms of pain, function or quality of life to taking an opioid. And perhaps even more interesting was the long term results, which was that the people in the opioid group actually fared worse over 12 months. And at the 12 month time point, they had worse pain on average than the people that took a placebo.

ROBYN WARD

And can you tell me what people on the placebo group actually had? Because they weren't just sort of decided that they had to go and grin and bear the pain did they? They had, they had some treatment, but what was the nature of that treatment that both groups got?

CAITLIN JONES

So everyone in the study got what we called guideline recommended treatments. So there were no restrictions on what doctors could prescribe for those patients. We just asked them to report what they did. So some people were sent off to physiotherapy. Some people were supplemented with other pain medicines like non steroidal anti inflammatories, like ibuprofen or paracetamol even. But we asked everyone to report what else they did. And there were no differences between groups. So on average, people went off and did about the same thing. It was really only the opioid that was the difference between those two groups.

ROBYN WARD

And based on your study and the rigor of that study, do you think that opioids should now be removed from any guidelines? Or are there still more work to be done before we remove the recommendations in some guidelines to continue to consider opioids for back pain,

CAITLIN JONES

I do think they should be removed for guidelines for acute back and neck pain, seeing as that was the population of the OPAL trial. And we got a really clear signal that there are just no benefits for that population. The OPAL trial looked at acute pain. So the recommendation is essentially to not start new users on opioids that have acute episodes of pain, but it's a whole different kettle of fish, people that have chronic pain, especially those that are already long term users of opioids. So the OPAL trial doesn't really give any answers to that population. And there are risks associated with abruptly stopping people on opioids. So we don't want the OPAL trial results to be misinterpreted to mean that clinicians should cease prescribing of opioids to people with chronic pain who have been on them for a long time. Because that can be dangerous when done suddenly.

ROBYN WARD

And in the study you you use the term back pain generically. And I noticed you have a larger group, who had low back pain and a relatively small number of people who had neck pain. And so I have a question around whether you think that these findings of not using opioids equally apply to people with low back pain, as well as people with neck pain.

CAITLIN JONES

It's true that our sample was majority back pain, I think it was maybe 80%, and only a small fraction of people had neck pain. So we were a bit underpowered to make really conclusive comments about neck pain. But the data we did see in the study that it wasn't any different. There doesn't seem to be any benefits for acute neck pain, either.

ROBYN WARD

And so why do you think Well, well, first off, what are the causes of low back pain, this acute low back pain? And why do you think opioids don't work?

CAITLIN JONES

Well, back pain is so complicated. Pain is so complicated. So you know, pain can be because of a physical injury, like some physical damage that leads to pain. But we also know you can experience pain when there's no identifiable physical damage there. You know, we know it's related to stress and lifestyle, as well as potentially physical damage. So it is really complicated. So when you think that there are so many different causes, and that the opioid only targets one kind of pain, which would be that, you know, pain related to physical damage, I guess it makes sense why it wasn't, you know, one simple treatment wasn't effective to treat such a complicated condition. And

ROBYN WARD

that's a that sort of leads me on to this next question, because there's so little in the way of diagnostic specificity in low back pain, how are we going to move the field forward so that we have better precision around the diagnosis and maybe there are subgroups of people within that, that opioids would work in or other treatments, but it's It's a sort of a big group of people who have different types of pain and different types of low back pain all get lumped together.

CAITLIN JONES

Yeah, that's such a good question. And it's a discussion that's happening in the field. Now, for a while we were moving away from trying to subgroup people. And we were sort of anyone who didn't have a obvious identifiable cause of back pain was given this label of nonspecific back pain. And they're the people we included in the opioid trial. So it's your garden variety, back pain, where there's no obvious cause, so people that perhaps had a fracture in runner, their vertebrae, or some sort of malignancy or infection, they weren't included in the opioid trial. So those serious pathological causes for back pain. And the findings of Opal don't necessarily apply to them. There is maybe more recently a bit of push back in the other direction that maybe we should be looking more closely at what subgroups exist. And seeing as most treatments we test don't work on average, across the board, maybe we do need to look at smaller, smaller groups of people and find things that work for smaller subgroups. And

ROBYN WARD

Do you have any views on their place of imaging in low back pain is, is that a bit beyond the remit of this study? But do you have any views yourself on whether people with low back pain should go along and have MRIs and CTS,

CAITLIN JONES

I'm not an expert what I do know in the literature is that while we don't really know how to subgroup people and treat them differently, there's no real benefit from going along and getting something like an x ray or an MRI, because you may find something a change that could be related to your pain, it could not be it could be a just a normal age related change, that then it sort of sets you on this pathway to get potentially unnecessary treatment, you might end up being referred for surgery to correct that structural damage they've seen. Whereas we don't know if that's actually causing your pain at all. And often it's not, because people go on to have them treated with surgeries and their back pain doesn't improve. So the way things are now, to go and get imaged is more likely to cause you harm than to actually help you solve your problem.

ROBYN WARD

Yeah, that's a great answer. And great advice as well, I think to people out there. So now, you're in this new world where you've done your study, and people will not be potentially using opioids anymore as a result of your important study. What are you going to advise? Or what should general practitioners and other people advise people who come into their rooms with low back pain? Take us through this sort of high level guidelines?

CAITLIN JONES

Yeah, sure. So people that first present with back pain, if it's acute, chances are, it's going to get better. So some reassurance to person to tell them that if they just do their best to maintain their normal activities, there's a very likely chance that they will feel better without any intervention. If that person does feel like they need some sort of intervention, non-steroidal anti-inflammatory drugs do seem to have the best benefit, harm balance they do have moderate benefits, and in most populations, only small harms. So that would be the go to medicine to turn to if you do feel like you need to turn to a medicine. For people with more chronic and complex back pain, there's recently been two really interesting studies called the resolve trial and the restore trial that have tested these complex multifaceted interventions with people and found really promising effects.

ROBYN WARD

And what are those interventions.

CAITLIN JONES
One is cognitive functional therapy. So it's, I guess, looking at the whole person and coming at it from a whole heap of different angles, which makes sense when you think that back pain has so many complicated causes. So yeah, those two trials have showed some effects where everyone in the back pain space was getting a bit depressed, because trial after trial, we just we keep finding things that don't work. But it's often the individual treatments don't work. But when you sort of help someone with this comprehensive program that helps them tackle all the different areas of their life that might be contributing to back pain. That's where we see the best effects. So I think that is where treatment for back pain is heading.

ROBYN WARD

And I was just curious, this study, it took quite a long time to recruit and finish. And I thought, well, the back pain is so common, you know, why would it take so long to recruit 300 odd patients? And I think ir was like four years or is that right?

CAITLIN JONES

Even longer!

ROBYN WARD 

Even longer? Okay, for more than four years. And so what does that tell us about the sorts of we the community engagement, we need to actually advance these fields because if it takes four or five years to recruit to just this study, then we're not going to advance the field of back pain if it's such a slow process.

CAITLIN JONES

We joke throughout the study that we've cured back pain, the best way to cure it is to go looking for people that have it and suddenly they all disappear. But it is so common and there's people with back pain all over the place but to find One who is willing to join a placebo-controlled study, it's quite a unique person because they have to agree to a 50/50 chance of getting either a strong and controversial pain medicine or a placebo, which they know is nothing. So often people had a strong preference, they'd say, Oh, I'll join as long as you can guarantee me an opioid. Or I'll join as long as you can guarantee me the placebo. But to find a person that would really be happy either way, is rare. So that's why it took so long. And I think that the answer going forward is for us to do an even better job at embedding clinical trials into regular practice, which is not so easy with placebos. But in other trials, where you're comparing two treatments to just be running trials in the natural healthcare system, so that no one has to go out of their way to join a study or a clinician doesn't have to go out of their way to recruit a patient to a study. And I think that will help us get important answers much faster.

ROBYN WARD

And I think that's often under appreciated. I know in the field that I work in, in cancer, clinical trials have become part of clinical practice, really, it's so embedded, it's sort of you can't separate the two. But in these other areas where you have huge morbidity, People are seemingly less engaged as a community in in understanding the importance of doing trials like this, because, you know, I imagine there's a lot of people whose take who have taken opioids, perhaps inadvisedly, now, over the last four years, if they had have had the opal trial results, their doctor or would not have prescribed an opioid. So that that's what those delays mean, in practice.

CAITLIN JONES

Yeah, I agree. I think it's also challenging when you're testing a treatment that's been around for a long time, it's not like we could offer a new exciting treatment. It was something that people could access easily outside the trial anyway. And so to convince them why they should take extra time and effort, you know, while while they're unwell with back pain to, to join a study to take a medicine that they could easily get outside the trial. It's a bit of a hard sell. So we really appreciate everyone that was that volunteered to join.

ROBYN WARD

It's been great talking to you today. Caitlin, congratulations on your study. Maybe you can just tell us what's next for you in your research career?

CAITLIN JONES

Well, so yeah, after looking at back pain, which is sort of, one of the biggest reasons for over prescription and inappropriate prescription of opioids, it seems like the next thing to look at is post surgical pain, because that's sort of the next biggest area where we think there's overuse and misuse of opioids. So our next plan is to tackle how effective opioids are used after surgery like hip and knee replacement.

ROBYN WARD

That is fantastic work. And I think everyone listening would be aware of the downsides of opioids. I don't think we need to provide any information on that. But I think it's very, very well-known abuse of opioids and their consequences to people, their families and how addictive they are

CAITLIN JONES

To whole communities as well.

ROBYN WARD
Exactly, it's been great talking to you, Caitlin, we really wish you all the best. And this is Research Bytes

CAITLIN JONES

Thanks for having me.

ROBYN WARD

So thank you for joining us on Research Bytes, and we came to you from Gadigal land

Dr Nick Hunt and his colleagues have been using nanotechnology to take us even closer to an oral insulin, negating the need for injections.

• Listen on Spotify
• Read the publication

PROFESSOR ROBYN WARD: 
So hi there, and welcome to Research Bytes, a podcast from the Faculty of Medicine and Health which explores the work of our early and mid-career researchers. I'm Executive Dean Professor Robyn Ward, and in this episode, I'm catching up with Dr. Nick Hunt from the School of Medical Sciences, who has done some pretty amazing work on oral insulin.

And I'm very keen to hear what he's got to say about his work. But before we get started, I thought it would be great just to hear a little bit about Nick. What have you done in your career? What's taken you to this point of working on diabetes and insulin?

DR NICK HUNT: 

A pleasure to be here and thank you very much for the invite to do this.

I've been a Sydney Uni person for a long time. So, I did my undergrad here, I did my PhD here, and aside from a brief stint over in NSW Health for about three months, I've been here for almost 10 years in research, so a good decade. So, the reason we have particularly focused on insulin and diabetes is when I finished my PhD, I jumped over from neuropathology and focused more on liver pharmacology.

And an amazing group at Anzac Research Institute as part of the Sydney Local Health District with Victoria Cogger. And the amazing team we've got together with Vic and David Le Couteur, who's the clinician of the hospital, is we started developing nanotechnology platforms for drug delivery. We were originally trying to target certain areas in the liver, called the liver sinusoidal endothelial cells, or the LSEC, and we're trying to look at how we can reverse age related changes with nanotechnology.

So, it was an incredibly fortunate time since when I finished my PhD, I got a one-year job with Vic, and then we were successful, well Vic was successful, getting an NHMRC grant. So that kind of then became the focus for us for the next three to four years, and then to kind of build on that.

So, we started off making nanotechnology platforms, and then we slowly branched into what else could we deliver with this technology. And one of the main problems facing clinicians in the hospital, as David pointed out, was the delivery of insulin if you've got a frail, older patient. One of the things that limited them from being able to go home from hospital, was that they'd have to have an initial management plan and would need someone to administer it.

So usually, it's either a nurse or you need a diabetic educator to come and instruct the family. So, we wanted something that's going to be safe and orally available. That's kind of how we morphed into the diabetes space because it's a question I do usually get, of ‘you work on nanotechnology, we have no experience in diabetes prior to 2018’, and that's how it slowly grew into it.

PROFESSOR ROBYN WARD: 
So, I mean, what I know about diabetes, what a lot of people know is that there's a lot of people in the world with diabetes, maybe close to 500 million, about say a hundred million of them are dependent on insulin. And for those people who are dependent on insulin, it's manageable when they're older.

As you say, but older people have trouble managing needles and insulin, but for a child with diabetes who is, who needs to take insulin from when they're very little, that exposes them to a lifelong exposure of insulin and and all the risks that are associated with taking insulin apart from injecting themselves forever.

So many, many decades, people have been talking about oral insulin and, and its promise and how amazing it would be. And we'll get onto the topic of hypoglycaemia soon, but, but why do you think your inventions are going to tackle this issue of oral availability, whereas many decades of work has failed to do so.

DR NICK HUNT: 

Yeah. So, it's been something that's been around for a good 60 years, the idea of oral insulin. I mean, insulin itself was discovered over 100 years ago. We had the anniversary last year.  It's an incredibly difficult area to go into and the main challenge is associated with its bioavailability and of course the costs associated with insulin.

So, insulin typically has a bioavailability of only 1 percent and we, with our technology have moved that up to 4%. So, a substantial increase but the main promise I think that we have from our technology is when we started looking at small pieces of tissue from human samples, we can get up to 40-fold more increase within the intestine of human patients, which is really exciting in an in vitro setting. We'll get to in vivo very soon. 

But that's part of the challenge associated with it.  As you were pointing out before, it's a combination of children that will be exposed and what we really tried to design with this technology is we pictured, if a clinician's sitting there in front of a child that's just been diagnosed, usually you do a titration series where you give them a tiny bit of insulin, see how they respond, then 15 20 minutes later, check their blood glucose, and then give them a tiny little bit more.

One of the challenges of oral insulins is they take over an hour in order to work.  So, what we designed is an insulin that would work within 15 minutes, so it could be at that first point of contact, so the patient would never actually need to go into injectable needles.  But it's not just on the child end, it's also on the type 2 diabetics, since that's the quite large and emerging market.

So, these are usually more elderly gentlemen, who really don't want to go on injectable insulin, so they will delay treatment for months, even a year, just to not have to do it. And if you can replace that with a tablet, it can be a lot easier, and it's also something we learned from the COVID pandemic.

People don't like taking injections at all, particularly around the vaccinations, but to be able to address that with an oral formulation can be a lot better and a better use for them.

PROFESSOR ROBYN WARD: 

And in your paper, which I read with great interest, there's a lot of complex terminology there. And part of this series is really trying to explain some of that in lay language, or at least in scientific language that your colleagues in the faculty and elsewhere can understand.

So, you talk a lot about quantum dots, and maybe you can explain what a quantum dot is and how do you get insulin onto a quantum dot?

DR NICK HUNT: 

Yeah, so quantum dots are an incredibly cool material, and they won the Nobel Prize for Chemistry earlier on in this year (2023).

So, quantum dots are a form of nanotechnologies. A nanotechnology is something that's between one to a hundred nanometres in size. And the usual way I get people to think about this is if you look at your finger, that's one centimetre across, you're talking about something that's a millionth the size of that.

And for another size comparison, think of the size of a soccer ball, and think of the size of the planet Earth. That's kind of the weird size dynamic that you've got.  The reason why we quite like quantum dots is they exist in the realm between what is something that can't pass between the gaps in cells.

So, they can't freely move throughout your entire body, but they are something that would be quite readily cleared by certain cells that would be in your liver. So, we've been exposed to nanomaterials for eons. Any grinding material, chewing food will create some level of nanomaterial. But quantum dots are a very small formulation of that which will be taken up by certain cell types in the body, and the body's developed that technique to clear those materials. So really, we're just cheating off something that's been developing for thousands of years of how our body would usually get rid of those materials, but we're using it to be able to transport something into the body that would then be rapidly cleared out, but they could release a payload or deliver a drug at that time point before they get cleared out of the body.

PROFESSOR ROBYN WARD: 

And how do you make one of these little quantum dots with a little insulin molecule sitting on it?

DR NICK HUNT: 

So, it's the challenge as we slowly start moving towards translation of this tech.

So right now, we're going through manufacturing of this to good manufacturing standards.  And the difficulty is, quantum dots are used quite a lot, but people would think about them, they're in their television sets. They're not something that's usually a pharmacological material. So how you do actually make them is the same process that you would for any other type of engineering material.

What we use is what is usually referred to as a hot injection method, where it really requires superheating of materials, till, effectively, if you think about a product that's been all clumped together, when you heat it a lot, it starts expanding quite quickly, and it starts, the term is nucleation, and you get separation of all these individual atoms.

And then as you slowly control how they're heated properly, they'll start forming quite complex shapes, and that's when you can start getting quantum dot formation. How you make those then, in a pharmacological setting and a biological setting, took a lot of work. But we slowly developed a process that can be implemented in a biological lab.

We did an R&D version of this, then moved on to a non GMP version, and then finally now moving to a, an accredited standard approach. So, it's required a lot of, so within the Australian context, CSIRO, who we partner for the non GMP work, was the first time they'd ever done anything like this. And it's the first-time quantum dots will be used in clinical trials for these particular purposes.

PROFESSOR ROBYN WARD: 

And what were the big scientific challenges around using quantum dots for this purpose? What, what sort of paradigms did you need to establish, and rules you needed to break.

DR NICK HUNT: 

Probably the chief rule is around the, the composition that we had. So, quantum dots, um, because they were designed, of course, for, for non-human purposes, uh, they've got really good versions that are not quite toxic to people.

We needed to develop a formulation that had a, a low level of toxicity associated with it. So, our ones are made up of silver and sulphur. But also start working around the idea of if you are going to be giving silver to patients, how much silver can they have? And the example I always love to give is if you're going to have our oral insulin formulation, there is more silver in a set of vegetables than there would be in that particular nanoparticle complex.

But it's a hard idea to kind of work around.  Aside from that, thinking about how we kind of grow with scale component of it. So, we're, of course, used to working in a small, tiny lab, but we needed to start making gram quantities of these materials. And it's a slow process. That's quite a lot of re-evaluations at each step.

But it's had an amazing team that's kind of brought together a lot of expertise in that space. And it's great to see that we now actually are ready. to make those kinds of quantities.

PROFESSOR ROBYN WARD: 

And one of the key advantages of, apart from being oral, is this avoidance of hypoglycaemia, which is a pretty terrible experience for any patient or a family member or a friend who's seen someone experience that, particularly in the evenings.

When I mean the evenings, I mean sleeping through the night and being hypoglycaemic is a real worry for mums and dads looking after kids with insulin dependent. So, what did you find in terms of hypoglycaemia? Is this a, an important finding for you? I mean, hypoglycaemia is the most important aspect of, of this particular technology.

DR NICK HUNT: 

So, within Australia, there's 64,000 hypoglycaemic events each year. For those patients or even their parents, half of them will call triple zero and then ten percent of them will need to go to hospital for treatment.  To be able to avoid that is incredibly important, but it's not just for the short-term complications, also for the long term.

So, the, the main energy that we're putting into a lot of diabetic management at the moment is trying to keep people in an optimal glycaemic range to try and limit the, the impact of, of nephropathy, so of retinopathy later on down in life. So, the way we went around designing this technology was to try and address that hypoglycaemic problem.

And what we aim to do is create a technology that only targets certain areas in the body. Uh, so that's where we started to target the liver. So traditionally of injectable insulin, you're giving very high non physiological dosages of insulin that will accumulate liver, muscle, and fat and almost take all the glucose out of the body instantaneously.

What we designed was technology that more closely replicated what happens physiologically of insulin. So, it's released from the pancreas, majority of it will work from the liver, and then a small amount will reach muscle and fat.  What we also did with this technology is we designed a polymer that would react to its environment to control how insulins released.

So, the polymer we have is designed to be degraded by enzymes that are released in response to high blood glucose levels. So, the net effect of that is when there's no glucose within the blood, or there's very low glucose environments, you don't get the release of the insulin payload. And this is actually something we discovered around COVID vaccines, since, um, 50 percent of it will just be excreted quite freely.

Nanomaterials are quite quickly cleared from the body. And if it doesn't have a release of its payload, it just gets taken out. So, it's not going to sit around and work. 24 hours, 48 hours later, you've got something where it's either the glucose is there, it's got the enzymes to release, to release that payload, or the material is cleared out.

So that's how we get that safety component. And one of my favourite lines from this tech is we've had in mice, rats, and baboons over a thousand data points, and we couldn't induce a single hypoglycaemic episode.  It's, it's great to see, uh, but you can just increase the safety profile of what insulin is. So, like, insulin typically, if you were to double the dosage, you can induce a hypoglycaemic episode.

With our technology, you need to have, uh, 20 times more. Uh, increase in the amount of insulin that you give in order to get that hypo. 2024 is the year of manufacturing and 2025 will be the year of clinical trials. Uh, so with this technology, of course, uh, we go through a traditional, um, what would it be, a commercial development process.

We've gone through and patented the technology; we then licensed it to a company and then that company is now leading it as it goes through to clinical trials.

PROFESSOR ROBYN WARD: 

Fantastic. And I know that everyone always thinks that a lot of research takes a lot of time, which is a very true statement. It does take a lot of time.

So how long did it take you from the day you begun on this project to where you are now? How many years has that been?

DR NICK HUNT: 

So, this has been a while. I think we originally got the grant to work on just kind of area in 2018. I've actually got a photo of the day when we actually discovered the, the polymer, because it really was a moment of, that doesn't actually look right, for how it was actually reacting in its environment.

And it turned out to be the formulation that went forward. So that was in mid 2019. What's crazy is when you go through and you're developing something for commercial translation, you can't talk about it for a long time. So, I had to sit there in conferences and people kind of go, Oh, okay, no, that's impossible.

It can't work. And I was sitting there going, we have data that already proves this. And you get there three years later and everyone's kind of going, awesome. But it's, it's a long time. So, this has taken up to, I suppose, five years for these steps. And I suppose getting it all the way through into patients and even to the phase two or phase three clinical trials, you're looking at another five years on top. Ten-year pipeline is usually how it works, and I like to think we're, we're nearing halfway.

PROFESSOR ROBYN WARD: 

So, this is, I think, such an exciting discovery that you've made. It was really a series of discoveries, very clinically applied, addressing a really big unmet need. And it's amazing that you've been able to do this here at the University of Sydney.

And it's been fantastic talking to you today about your discoveries. And I hope that people listening out there will really be inspired by what Nick and Victoria Cogger and David Le Couteur and many other people have done to bring this to fruition and are enjoying our very first episode of Research Bytes.

Thanks for listening.  You can listen back, read the paper and find the transcript on soundcloud.com/fmh-news.

 ​